Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 128, Issue 2, Pages 293-302Publisher
SPRINGER
DOI: 10.1007/s11060-016-2109-x
Keywords
Pediatric glioma; Oligodendroglioma; Glioneuronal; Leptomeningeal neoplasms; Protooncogene proteins B-raf
Categories
Funding
- A Kids' Brain Tumor Cure Foundation Pediatric Low-Grade Astrocytoma Foundation
- Stop and Shop Pediatric Brain Tumor Program
- St Baldrick's Foundation
- Team Jack Foundation
- Andrysiak Fund for LGG
- Jared Branfman Sunflowers For Life Fund For Pediatric Brain And Spinal Cancer Research
- Sontag Foundation
- Nuovo-Soldati Foundation
- Philippe Foundation
- Pediatric Brain Tumor Foundation
- Royal Children's Hospital Foundation
- Robert Connor Dawes Foundation
- Murray Jackson Clinical Fellowship, Genesis Oncology Trust, New Zealand
Ask authors/readers for more resources
Disseminated glioneuronal tumors of childhood are rare. We present a retrospective IRB-approved review of the clinical course and frequency of BRAF mutations in disseminated glioneuronal tumors at two institutions. Defining features of our cohort include diffuse leptomeningeal-spread, often with a discrete spinal cord nodule and oligodendroglioma-like histologic features. Patients were identified through a pathology database search of all cases with disseminated low-grade neoplasms with an oligodendroglioma-like component. De-identified clinical information was collected by chart review and all imaging was reviewed. We retrieved the results of targeted genomic analyses for alterations in BRAF. Ten patients (aged 2-14 years) were identified from the Dana-Farber/Boston Children's Hospital and the Royal Children's Hospital, Melbourne pathology databases. Nine patients received chemotherapy. Eight patients are alive, although three have had episodes of progressive disease. We identified genomic alterations affecting the MAPK pathway in six patients. One patient had a germline RAF1 mutation and a clinical diagnosis of cardio-facio-cutaneous syndrome. BRAF duplications were identified in four and BRAF V600E mutation was identified in one. These data support the presence of targetable genomic alterations in this disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available